Avelas Biosciences
Innovative intraoperative cancer detection with AVB 620, enhancing surgical precision and patient outcomes.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | N/A | - | |
| Total Funding | 000k | ||
Related Content
Avelas Biosciences is a clinical-stage oncology company dedicated to improving cancer surgery outcomes through its lead product, AVB 620. AVB 620 is a novel drug-device combination designed to detect cancer in real-time during surgery, allowing surgeons to identify and remove cancerous tissue more accurately. This technology aims to become a standard part of care in various cancer surgeries, including ovarian, colorectal, head and neck, lung, and melanoma. Avelas operates in the medical and healthcare market, primarily serving surgeons and hospitals. The company generates revenue through the development and potential future sales of its innovative cancer detection products.
Keywords: intraoperative cancer detection, AVB 620, oncology, real-time imaging, surgical precision, drug-device combination, cancer surgery, clinical-stage, healthcare innovation, patient outcomes.